12th May, 2023: TechInvention Lifecare Pvt. Ltd., India, has partnered with M/s. Eubiologics Co., Ltd. (Eubiologics), South Korea, to launch Euvichol-Plus, the world’s first and only oral cholera vaccine (OCV), in a low-density polyethylene (LDPE) unidose pack in India.
The LDPE unidose pack of Euvichol-Plus is not only easy and safe to use, but it also reduces the issues pertaining to conventional glass vials in terms of breakage, storage, transportation, distribution, waste management, and facilitates delivery in emergency situations and humanitarian crises in campaign mode.
While cholera remains a major global public health threat, there has been an alarming resurgence of cases in susceptible countries globally amidst the stoppage in production of one of the only two cholera vaccines.
India features at the top of the list of cholera- endemic countries, with an estimated incidence rate of 1.64 per 1,000 people. In India, estimates show that 400 million people are at risk of cholera, with an estimated 6,751,888 cases and 20,256 (3%) deaths annually. From 2011 to 2020, 565 outbreaks were reported in India that led to 45,759 cases and 263 deaths. This represents only the tip of the iceberg, as cholera remains an under-recognized health issue and is grossly under-reported in India. An effective cholera vaccine has long been the vision for controlling cholera in India.
“In this joint effort with Eubiologics to bring a preventive solution to the recurring endemic that is cholera, the launch of Euvichol-Plus is the empirical choice,” said TechInvention’s Founder and CEO, Mr. Syed Ahmed. “We wish to contribute to the national initiatives along the lines of WHO’s ‘Ending Cholera: A Global Roadmap by 2030’. TechInvention has 2 more vaccines in late-stage clinical development and regulatory approval in India, while there are more on the anvil” he added.
Eubiologics’ CEO, Mr. Yeong-OkBaik, mentioned, “We are happy to have collaborated with TechInvention and to bring our WHO-prequalified cholera vaccine, Euvichol-Plus, in a unidose pack to India. We hope to make a difference in the lives of Indian children and contribute to the reduction of disease prevalence by increasing vaccine coverage wherever it is needed. The positive outcome of the clinical study encourages us to take part in similar initiatives.